Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients
Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients
复制标题
DOI：
10.1002/mds.20387
复制
发表时间：
2005-06-01
影响因子：
8.6
通讯作者：
Hattori, T
中科院分区：
文献类型：
--
作者：
Liu, Z;Sakakibara, R;Hattori, T
枸橼酸莫沙必利是一种新型的选择性5-HT4受体激动剂。它促进乙酰胆碱从肠胆碱能神经元释放。与西沙必利相反。莫沙必利不阻断K+通道或D2多巴胺能受体，本研究的目的是对莫沙必利对便秘的影响进行一项开放研究，便秘是帕金森病患者的一种突出的下消化道疾病。共有14例帕金森病患者（7例伴有帕金森病，7例伴有多系统萎缩；10例男性，4例女性-，平均年龄67岁）伴有便秘（10例排便< 3次/周-，14例排便困难），接受15mg /天的枸橼酸莫沙必利治疗3个月。获得治疗前后结肠运输时间（CTT）和直肠视频测压的客观参数。采用Student’st检验进行统计分析。除1例患者因胃脘不适停用莫沙必利外，所有患者均耐受良好。没有人病情恶化。13例患者报告主观上改善了排便频率（3次/周）。13)和排便困难（13）。莫沙必利缩短直肠填充时左结肠CTT （P = 0.01）和全结肠CTT （P = 0.05）。莫沙必利减轻了第一感觉（P < 0.05），增加了相性直肠收缩的幅度。在排便时，莫沙必利增加直肠收缩幅度（p = 0.05），减少排便后残余量。本研究首次表明，枸橼酸莫沙必利可增强下胃肠道功能。CTT和视频测压显示，从而改善了帕金森患者的便秘，没有严重的不良反应。(c) 2005年运动障碍协会
Mosapride citrate is a novel selective 5-HT4 receptor agonist. It facilitates acetylcholine release from the enteric cholinergic neurons. In contrast to cisapride. mosapride does not block K+ channels or D2 dopaminergic receptors, The objective of this study is to perform an open study of mosapride citrate's effects on constipation, a prominent lower gastrointestinal tract disorder in parkinsonian patients. A total of 14 parkinsonian patients (7 with Parkinson's disease, 7 with multiple system atrophy; 10 men, 4 women-, mean age, 67 years) with constipation (10 with bowel movement < 3 times/week-, 14 with difficulty in defecation) were treated with 15 mg/day of mosapride citrate for 3 months. Pre- and posttreatment objective parameters in colonic transit time (CTT) and rectoanal videomanometry were obtained. Statistical analysis was made by Student's t test. Mosapride was well tolerated by all patients except for 1, who discontinued use of the drug because of epigastric discomfort. None had it worsening. of parkinsonism or other adverse events, Thirteen patients reported subjective improvements ill bowel frequency (3 times/week. 13) and difficult defecation (13). Mosapride Shortened CTT of the left colon (P = 0.01) and the total colon (P = 0.05), During rectal filling. mosapride lessened the first sensation (P < 0.05) and augmented the amplitude in phasic rectal contraction. During defecation, mosapride augmented the amplitude ill rectal contraction (p = 0.05) and lessened the volume of postdefecation residuals. The present study showed for the first time that mosapride citrate augmented lower gastrointestinal tract niotility. as shown in CTT and videomanometry, and thereby ameliorated constipation in parkinsonian patients, without serious adverse effects. (c) 2005 Movement Disorder Society